Irlande - anglais - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - clindamycin - capsule, hard - 150 milligram(s) - lincosamides; clindamycin

Arménie - anglais - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fareva amboise - clindamycin (clindamycin hydrochloride) - capsules - 150mg

Arménie - anglais - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fareva amboise - clindamycin (clindamycin hydrochloride) - capsules - 300mg

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

pfizer pharmaceuticals inc. - clindamycin hydrochloride - opaque orange/opaque pale orange capsule

Australie - anglais - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: shellac; magnesium stearate; titanium dioxide; iron oxide black; purified talc; maize starch; lactose monohydrate; gelatin; propylene glycol; strong ammonia solution - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Canada - anglais - Health Canada

pfizer canada ulc - clindamycin (clindamycin 2-palmitate hydrochloride) - granules for solution - 75mg - clindamycin (clindamycin 2-palmitate hydrochloride) 75mg - lincomycins

Irlande - anglais - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - clindamycin - capsule, hard - 150 milligram(s) - antiinfectives for treatment of acne; clindamycin

Irlande - anglais - HPRA (Health Products Regulatory Authority)

imbat limited - clindamycin - capsule, hard - 150 milligram(s) - lincosamides; clindamycin

Irlande - anglais - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - clindamycin hydrochloride - capsule, hard - 150 milligram(s) - lincosamides; clindamycin

Malte - anglais - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - clindamycin - hard capsule - clindamycin 150 mg - antibacterials for systemic use